Pirfenidone (Esbriet)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Idiopathic Pulmonary Fibrosis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (1)
EU
  • Esbriet is indicated in adults for the treatment of idiopathic pulmonary fibrosis.
Product first approved 2011EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (16)
Idiopathic Pulmonary Fibrosis
NCT03208933 · Hoffmann-La Roche
2017-10-23 – 2019-11-13 · Idiopathic Pulmonary Fibrosis
What this study did
NCT00662038 · Genentech, Inc.
2008-08 – 2016-02 · Idiopathic Pulmonary Fibrosis
What this study did
Other / comorbidity
NCT06928272 · Douglas D. Fraser
2025-09-10 – 2027-12 · Long COVID
What this study did
NCT05075161 · Università Vita-Salute San Raffaele
2022-06-01 – 2026-12 · Acute Respiratory Distress Syndrome (ARDS)
What this study did
NCT05288179 · Beijing Continent Pharmaceutical Co, Ltd.
2022-06-07 – 2026-09-30 · Pneumoconiosis
What this study did
NCT05713292 · Capital Medical University
2022-12-01 – 2023-03-30 · COVID-19 Pneumonia
What this study did
NCT03856853 · Beijing Continent Pharmaceutical Co, Ltd.
2018-06-15 – 2021-05-10 · Systemic Sclerosis-associated Interstitial Lung Disease (Ssc-ild)
What this study did
NCT03857854 · Beijing Continent Pharmaceutical Co, Ltd.
2018-06-05 – 2021-05 · Dermatomyositis Interstitial Lung Disease (Dm-ILD)
What this study did
NCT04282902 · Huilan Zhang
2020-02-04 – 2020-06-01 · Novel Coronavirus Pneumonia, Pneumonia, Pirfenidone
What this study did
NCT02823236 · Centro Dermatológico Dr. Ladislao de la Pascua
2016-10-24 – 2020-05-01 · Keloid
What this study did
NCT02689778 · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
2016-03 – 2019-12 · Diabetic Nephropathy, Albuminuria
What this study did
NCT06909812 · Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C.
2015-07-14 – 2016-01-20 · Scars, Keloids, Hypertrophic Scar
What this study did
NCT02222376 · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
2013-10 – 2015-04 · Diabetic Foot Ulcers
What this study did
Phase 2/3 (4)
Other / comorbidity
NCT07388680 · Beijing Continent Pharmaceutical Co, Ltd.
2026-03-26 – 2026-12-30 · Radiation-induced Lung Injury, Immune-related Pneumonia
What this study did
NCT03068234 · RenJi Hospital
2017-05 – 2019-12 · Systemic Sclerosis
What this study did
NCT02262299 · Copenhagen University Hospital, Rigshospitalet
2015-05 – 2019-12 · Disorder Related to Lung Transplantation, CLAD, Bronchiolitis Obliterans
What this study did
NCT02496182 · Grupo Medifarma, S. A. de C. V.
2015-07 – 2017-01 · Alveolitis Extrinsic Allergic, Pulmonary Fibrosis
What this study did
Phase 2 (42)
Idiopathic Pulmonary Fibrosis
NCT06241560 · Boehringer Ingelheim
2026-03-05 – 2026-08-07 · Idiopathic Pulmonary Fibrosis
What this study did
NCT00080223 · Genentech, Inc.
2003-08-31 – 2015-04-30 · Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis
What this study did
NCT02136992 · Shanghai Pulmonary Hospital, Shanghai, China
2011-12 – 2013-12 · Idiopathic Pulmonary Fibrosis
What this study did
NCT01504334 · Beijing Kawin Technology Share-Holding Co., Ltd.
2012-01 – 2013-03 · Idiopathic Pulmonary Fibrosis
What this study did
Other / comorbidity
NCT07856914 · Patrick Wagner, MD, FACS
2026-09 – 2030-11 · Peritoneal (Metastatic) Cancer, Peritoneal Carcinoma, Peritoneal Carcinosis, Peritoneal Cancer, Peritoneal Carcinomatosis, Peritoneal Carcinomatosis From Colorectal or Ovarian Origin, Peritoneal Cavity Cancer
What this study did
NCT07755813 · Vikas Dudeja
2026-08 – 2030-08 · Chronic Pancreatitis
What this study did
NCT06253117 · University of Alabama at Birmingham
2024-06-27 – 2028-09-01 · Recurrent Acute Pancreatitis
What this study did
NCT05704166 · Fujian Medical University Union Hospital
2023-03-16 – 2027-12-31 · Acute Lung Injury, Prevention
What this study did
NCT07644286 · Tao Zhang
2025-12-01 – 2027-12-25 · Colorectal Cancer (CRC)
What this study did
NCT06484153 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2024-07-22 – 2026-12-30 · To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma, To Evaluate Whether Pirfenidone Can Reshape the Tumor Microenvironment in Colorectal Cancer, Combination of Fruquintinib and Anti-PD-1 Antibody Was Reported to Improve Patient Prognosis in Colorectal Cancer
What this study did
NCT05801133 · Hubei Cancer Hospital
2023-03-31 – 2025-10-31 · Lung Cancer
What this study did
NCT06142318 · Nanfang Hospital, Southern Medical University
2023-11-15 – 2025-06-30 · Head and Neck Squamous Cell Carcinoma, Radiotherapy, Radiosensitizer, Pirfenidone
What this study did
NCT04258397 · Veterans Medical Research Foundation
2020-10-26 – 2024-12 · Chronic Kidney Disease
What this study did
NCT05531955 · Shanghai Zhongshan Hospital
2022-08-05 – 2024-06 · Myocardial Fibrosis
What this study did
NCT05542615 · University of Guadalajara
2019-08-01 – 2024-01-01 · Liver Cirrhosis, Hepatitis C, Chronic, Epigenetic Disorder
What this study did
NCT03902509 · Beijing Continent Pharmaceutical Co, Ltd.
2019-05-24 – 2023-12-04 · Radiation-induced Lung Injury
What this study did
NCT05118256 · Instituto de investigación e innovación biomédica de Cádiz
2021-11-15 – 2023-11-15 · Silicosis, Progressive Massive Fibrosis, Complicated Silicosis
What this study did
NCT06267794 · Jorge L Poo
2015-06-26 – 2023-03-24 · Liver Fibrosis, Cirrhosis, Liver, Chronic Liver Disease
What this study did
NCT04193592 · Jesse Roman
2019-12-01 – 2022-12-31 · Hermansky Pudlak Syndrome, Interstitial Lung Disease
What this study did
NCT04461587 · Pulmonary Research of Abingdon, LLC
2020-08-31 – 2022-11-16 · Coal Workers' Pneumoconiosis (Complicated)
What this study did
NCT04607928 · Institut d'Investigació Biomèdica de Bellvitge
2020-08-01 – 2022-06-30 · Fibrotic Pulmonary Sequelae Post-COVID19 Infection
What this study did
NCT03221257 · Michael Roth
2017-11-28 – 2022-06-13 · Scleroderma, Systemic, Interstitial Lung Disease
What this study did
NCT03359863 · University of California, San Francisco
2018-03-07 – 2021-10-28 · Restrictive Chronic Lung Allograft Dysfunction, Lung Transplant Rejection
What this study did
NCT03473340 · University of Michigan
2018-04-27 – 2021-08-20 · Disorder Related to Lung Transplantation, Chronic Lung Allograft Dysfunction
What this study did
NCT02808871 · Brigham and Women's Hospital
2017-04-07 – 2021-04-07 · Rheumatoid Arthritis Interstitial Lung Disease
What this study did
NCT02958917 · Evans Fernandez Perez
2017-06-05 – 2021-03-02 · Interstitial Lung Disease
What this study did
NCT04099407 · Grupo Mexicano para el Estudios de las Enfermedades Hepaticas
2019-08-01 – 2020-12-31 · Liver Fibrosis, Chronic Liver Disease
What this study did
NCT03385668 · Assistance Publique - Hôpitaux de Paris
2018-01-31 – 2020-07-24 · Pulmonary Fibrosis
What this study did
NCT04675619 · Zagazig University
2019-12-01 – 2020-06-30 · Hypersensitivity Pneumonitis
What this study did
NCT02932566 · Manchester University NHS Foundation Trust
2017-03-02 – 2020-04-29 · Cardiac Failure
What this study did
NCT03099187 · Hoffmann-La Roche
2017-05-15 – 2020-01-10 · Lung Diseases, Interstitial
What this study did
NCT03530150 · Universidad Autonoma de Nuevo Leon
2017-01-01 – 2017-06-22 · Second-degree Burn
What this study did
NCT02296281 · Beijing Continent Pharmaceutical Co, Ltd.
2015-01 – 2016-06 · Radiation Pneumonitis
What this study did
NCT00001596 · William Gahl, M.D.
2005-09 – 2016-05-09 · Albinism, Inborn Errors of Metabolism, Oculocutaneous Albinism, Platelet Storage Pool Deficiency, Pulmonary Fibrosis
What this study did
NCT01933334 · Genentech, Inc.
2013-10 – 2014-09 · Systemic Sclerosis
What this study did
NCT00076102 · National Cancer Institute (NCI)
2004-07-21 – 2010-04-01 · Neurofibromatosis 1, Neurofibroma, Plexiform
What this study did
NCT00001959 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
1999-12 – 2008-10 · Fibrosis, Focal Glomerulosclerosis, Kidney Failure, Nephrotic Syndrome, Proteinuria
What this study did
NCT02161952 · University of Guadalajara
2005-05 – 2007-08 · Fibrosis, Hepatitis C Chronic
What this study did
NCT00332033 · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
2006-05-25 – 2007-02-16 · Uterine Leiomyoma, Fibroids
What this study did
NCT00754780 · Mayo Clinic
2000-09 – 2004-08 · Neurofibromatosis
What this study did
NCT00011076 · National Heart, Lung, and Blood Institute (NHLBI)
2001-02 – 2003-04 · Hypertrophic Cardiomyopathy
What this study did
Phase 1/2 (9)
Other / comorbidity
NCT03109288 · National Institute of Allergy and Infectious Diseases (NIAID)
2017-08-11 – 2029-01-01 · Multiple Sclerosis
What this study did
NCT07161791 · Harbin Medical University
2025-09-15 – 2027-12-31 · Breast Cancer, Triple Negative Breast Cancer (TNBC)
What this study did
NCT04467723 · University of Kansas Medical Center
2022-05-18 – 2027-08 · NSCLC Stage IV, NSCLC, Recurrent
What this study did
NCT05350371 · University of Alabama at Birmingham
2023-08-01 – 2026-02-26 · Pancreatitis, Acute
What this study did
NCT06871904 · Ziauddin University
2025-04-07 – 2025-12-30 · Oral Submucous Fibrosis
What this study did
NCT03076320 · University of Guadalajara
2017-03-27 – 2019-03-31 · Acne Vulgaris Superficial Mixed Comedonal and Inflammatory
What this study did
NCT02632877 · University of Guadalajara
2014-01 – 2015-12 · Diabetic Foot Ulcer
What this study did
NCT02408744 · University of Guadalajara
2009-09 – 2013-09 · Fibrosis, Chronic Kidney Disease
What this study did
NCT00063583 · Sharma, Kumar, M.D.
2003-06 – 2009-03 · Diabetes Mellitus, Diabetic Nephropathy
What this study did
Phase 1 (21)
Idiopathic Pulmonary Fibrosis
NCT05195918 · Hal Chapman
2023-08-24 – 2026-03-19 · Idiopathic Pulmonary Fibrosis
What this study did
NCT06569381 · Overseas Pharmaceuticals, Ltd.
2024-09-18 – 2024-12-08 · Idiopathic Pulmonary Fibrosis
What this study did
NCT06588517 · Overseas Pharmaceuticals, Ltd.
2024-04-08 – 2024-04-27 · Idiopathic Pulmonary Fibrosis
What this study did
NCT06589921 · Overseas Pharmaceuticals, Ltd.
2023-08-25 – 2023-09-14 · Idiopathic Pulmonary Fibrosis
What this study did
NCT05383131 · Sunshine Lake Pharma Co., Ltd.
2021-06-23 – 2021-11-30 · Idiopathic Pulmonary Fibrosis
What this study did
NCT07588646 · Sunshine Lake Pharma Co., Ltd.
2021-06-29 – 2021-11-30 · Idiopathic Pulmonary Fibrosis
What this study did
NCT04888715 · Daewoong Pharmaceutical Co. LTD.
2021-07-23 – 2021-08-18 · Idiopathic Pulmonary Fibrosis
What this study did
NCT03981094 · Bristol-Myers Squibb
2019-05-10 – 2019-07-30 · Idiopathic Pulmonary Fibrosis (IPF)
What this study did
NCT02648048 · Hoffmann-La Roche
2016-01-15 – 2016-11-30 · Idiopathic Pulmonary Fibrosis
What this study did
Other / comorbidity
NCT07654517 · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
2027-04-01 – 2030-03-31 · Idiopathic Subglottic Stenosis, Subglottic Stenosis (SGS)
What this study did
NCT07229716 · Guangdong Hengrui Pharmaceutical Co., Ltd
2026-04-04 – 2026-06-18 · Pulmonary Fibrosis
What this study did
NCT07015398 · Trevi Therapeutics
2025-06-30 – 2025-09-26 · Healthy Participants
What this study did
NCT03177291 · H. Lee Moffitt Cancer Center and Research Institute
2017-09-26 – 2024-12-04 · Lung Cancer, Non Small Cell Lung Cancer, Advanced Cancer, Metastatic Lung Cancer, Squamous Cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung
What this study did
NCT05280873 · Zhou Chengzhi
2021-10-10 – 2024-10-20 · Pneumonitis, Malignant Tumor
What this study did
NCT06070610 · Boehringer Ingelheim
2023-11-08 – 2023-12-14 · Healthy
What this study did
NCT04126538 · Beijing Continent Pharmaceutical Co, Ltd.
2019-08-27 – 2022-06-30 · Renal Insufficiency
What this study did
NCT04971746 · Lakefront Biotherapeutics NV
2021-07-19 – 2022-05-09 · Healthy
What this study did
NCT03315741 · Stanford University
2018-03-01 – 2022-04-27 · Bronchiolitis Obliterans, Graft Vs Host Disease
What this study did
NCT04939467 · Blade Therapeutics
2021-10-15 – 2022-04-01 · Drug Drug Interaction
What this study did
NCT02525484 · Hoffmann-La Roche
2015-08 – 2015-08 · Healthy Volunteer
What this study did
NCT00053937 · National Cancer Institute (NCI)
started 2002-12 · Neurofibromatosis Type 1, Precancerous Condition
What this study did
Phase 4 (13)
Idiopathic Pulmonary Fibrosis
NCT03939520 · Hospices Civils de Lyon
2020-06-11 – 2026-01-09 · Progressive Idiopathic Pulmonary Fibrosis
What this study did
NCT02598193 · Hoffmann-La Roche
2016-01-14 – 2017-05-16 · Idiopathic Pulmonary Fibrosis
What this study did
NCT02606877 · Boehringer Ingelheim
2016-04-19 – 2017-03-22 · Idiopathic Pulmonary Fibrosis
What this study did
NCT02579603 · Boehringer Ingelheim
2015-10-16 – 2017-01-31 · Idiopathic Pulmonary Fibrosis
What this study did
Other / comorbidity
NCT07325357 · Shanghai Zhongshan Hospital
2025-12-20 – 2030-12-31 · Takayasu Arteritis
What this study did
NCT07141810 · Shanghai Pulmonary Hospital, Shanghai, China
2025-10-01 – 2028-05-30 · Fibrotic Interstitial Lung Disease
What this study did
NCT05505409 · Qilu Hospital of Shandong University
2022-06-22 – 2025-12-01 · Pirfenidone, Connective Tissue Diseases, Interstitial Lung Disease
What this study did
NCT04928586 · Qilu Hospital of Shandong University
2019-08-16 – 2025-06-01 · Pirfenidone, Connective Tissue Diseases, Interstitial Lung Disease
What this study did
NCT06224790 · Sidrah Lodhi
2024-03-10 – 2025-03-07 · Diabetic Nephropathies, Type 2 Diabetes
What this study did
NCT04856111 · Post Graduate Institute of Medical Education and Research, Chandigarh
2021-03-17 – 2022-11-30 · Novel Coronavirus-induced Lung Fibrosis
What this study did
NCT03260556 · University of Cincinnati
2017-09-27 – 2020-03-30 · Sarcoidosis, Pulmonary
What this study did
NCT02821689 · RenJi Hospital
2016-07 – 2018-06 · Dermatopolymyositis, Interstitial Lung Disease
What this study did
NCT02530359 · Hospital Civil de Guadalajara
2015-10 – 2016-07 · Acute Kidney Injury, Sepsis
What this study did
Early phase / not applicable (5)
Idiopathic Pulmonary Fibrosis
NCT03692481 · Assistance Publique - Hôpitaux de Paris
2020-02-04 – 2024-04 · Idiopathic Pulmonary Fibrosis
What this study did
Other / comorbidity
NCT05133453 · Cairo University
2024-02 – 2026-02 · Asbestosis
What this study did
NCT04653831 · Soroka University Medical Center
2020-11-08 – 2022-12-31 · Covid19, ARDS
What this study did
NCT03539289 · Consorcio Centro de Investigación Biomédica en Red (CIBER)
2017-12-28 – 2020-04-22 · Pulmonary Disease
What this study did
NCT00020631 · National Cancer Institute (NCI)
2001-10 – 2007-10 · Radiation Fibrosis
What this study did
Used as active comparator (11)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (3)
Idiopathic Pulmonary Fibrosis
NCT07082842 · Sunshine Lake Pharma Co., Ltd.
2025-10-27 – 2032-02-15 · Idiopathic Pulmonary Fibrosis (IPF)
What this study did
NCT07284602 · PureTech
2026-06-26 – 2029-12 · Idiopathic Pulmonary Fibrosis (IPF)
What this study did
NCT07719023 · Shanghai Ark Biopharmaceutical Co., Ltd.
2026-08-31 – 2029-03-31 · Idiopathic Pulmonary Fibrosis (IPF)
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT06585319 · Materno-Perinatal Hospital of the State of Mexico
2020-02-01 – 2024-08-31 · COVID 19
What this study did
Phase 2 (4)
Idiopathic Pulmonary Fibrosis
NCT05060822 · Sunshine Lake Pharma Co., Ltd.
2021-06-30 – 2026-12-11 · Idiopathic Pulmonary Fibrosis
What this study did
NCT05321420 · PureTech
2022-07-22 – 2025-12-31 · Idiopathic Pulmonary Fibrosis
What this study did
NCT01890265 · Kyntra Bio
2013-07-30 – 2017-11-16 · Idiopathic Pulmonary Fibrosis
What this study did
NCT01872689 · Hoffmann-La Roche
2013-10-13 – 2017-11-06 · Idiopathic Pulmonary Fibrosis
What this study did
Phase 1 (2)
Idiopathic Pulmonary Fibrosis
NCT05428150 · Excalibur Pharmaceuticals, Inc.
2022-08-08 – 2022-09-25 · Idiopathic Pulmonary Fibrosis
What this study did
Other / comorbidity
NCT07456800 · PureTech
2021-07-12 – 2022-01-20 · Pharmacokinetic Analysis
What this study did
Early phase / not applicable (1)
Idiopathic Pulmonary Fibrosis
NCT05842681 · Assiut University
2023-06-01 – 2027-02-28 · Idiopathic Pulmonary Fibrosis
What this study did
Appears in other studies (3)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (2)
Idiopathic Pulmonary Fibrosis
NCT02707640 · Hoffmann-La Roche
2013-08 – 2015-02 · Idiopathic Pulmonary Fibrosis
What this study did
Phase 1 (1)
Idiopathic Pulmonary Fibrosis
NCT07454291 · Endeavor Biomedicines, Inc.
2026-04-28 – 2026-10 · Idiopathic Pulmonary Fibrosis
What this study did

Competitive landscape

This drug's own stage for Idiopathic Pulmonary Fibrosis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Pirfenidone (Esbriet): this drugApprovedSmall moleculePyridoneReliable signal
NCT01366209: At week 52, decline in percent predicted FVC of 10 points or more, or death: pirfenidone 16.5% vs placebo 31.8% (relative reduction 47.9%); no FVC decline 22.7% vs 9.7%; P<0.001 (ASCEND, NEJM 2014; CT.gov posted results).
Nerandomilast (Jascayd)ApprovedSmall moleculePDE4BReliable signal
NCT05321069: Absolute Change From Baseline in Forced Vital Capacity (FVC) [mL] at Week 52 (The MMRM model is a longitudinal analysis, and it incorporated FVC measurements from baseline (Week -8 to Week -1) and Week 2, Week 6, Week 12, Week 18, Week 26, Week 36, Week 44 and Week 52. The data represent the Least Squares Mean at Week 52): Placebo -183.48 Milliliters (mL) (95% CI -210.86 to -156.1) | Nerandomilast 9 mg BID -138.6 Milliliters (mL) (95% CI -165.59 to -111.61) | Nerandomilast 18 mg BID -114.65 Milliliters (mL) (95% CI -141.81 to -87.5)
NCT04419506: The Change From Baseline in Forced Vital Capacity (FVC) at 12 Weeks (Baseline (day 1) and week 12.): Placebo - Antifibrotics at Baseline -77.7 Milliliter (95% CI -124.87 to -30.53) | BI 1015550 - Antifibrotics at Baseline 2.72 Milliliter (95% CI -33.46 to 38.89) | Placebo - Non-antifibrotics at Baseline -95.62 Milliliter (95% CI -157.13 to -34.1) | BI 1015550 - Non-antifibrotics at Baseline 6.1 Milliliter (95% CI -39.67 to 51.88)
Nintedanib (Ofev)ApprovedSmall moleculeTriple angiokinase inhibitor (VEGFR/FGFR/PDGFR)Partial signal
NCT01335464: INPULSIS-1, annual rate of FVC decline over 52 weeks, nintedanib 150 mg twice daily (n=309) vs placebo (n=204): -114.65 vs -239.91 mL/year; difference 125.26 mL/year (95% CI 77.68 to 172.84), p < 0.0001 (CT.gov posted results).
NCT01335477: INPULSIS-2, annual rate of FVC decline over 52 weeks, nintedanib 150 mg twice daily (n=329) vs placebo (n=219): -113.59 vs -207.32 mL/year; difference 93.73 mL/year (95% CI 44.78 to 142.68), p = 0.0002 (CT.gov posted results).
Treprostinil (Tyvaso DPI)
Approved(overall)
Small moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
HSK44459Phase 3Small moleculePDE4Bnot yet gradedNo reviewed efficacy summary in this indication
Treprostinil (Tyvaso)Phase 3Small moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
ABBV-722
Phase 1(overall)
Small moleculeLPAR1not yet gradedNo reviewed efficacy summary in this indication
Iloprost (Ventavis)DiscontinuedSmall moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
PamrevlumabDiscontinuedMonoclonal antibodyCTGFnot yet gradedNo reviewed efficacy summary in this indication
Voxelotor (Oxbryta)DiscontinuedSmall moleculeHemoglobin S (HbS)not yet gradedNo reviewed efficacy summary in this indication
ZiritaxestatDiscontinuedSmall moleculeautotaxin (ENPP2)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(14 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Pirfenidone (Esbriet) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (4)
December 2026 (4)
Phase 3Long COVIDRecruiting
Est. primary completion 2026-12 · NCT06928272 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2026-12-01 · NCT07268677 · CT.gov ↗
What to watch
Phase 2/3Radiation-induced Lung Injury, Immune-related PneumoniaRecruiting
Est. primary completion 2026-12-30 · NCT07388680 · CT.gov ↗
What to watch
Phase 1/2Breast Cancer, Triple Negative Breast Cancer (TNBC)Not yet recruiting
Est. primary completion 2026-12-31 · NCT07161791 · CT.gov ↗
What to watch
2027 (4)
January 2027 (3)
Phase 1/2NSCLC Stage IV, NSCLC, RecurrentRecruiting
Est. primary completion 2027-01-01 · NCT04467723 · CT.gov ↗
What to watch
Phase 1/2Multiple SclerosisRecruiting
Est. primary completion 2027-01-01 · NCT03109288 · CT.gov ↗
What to watch
Phase 2Colorectal Cancer (CRC)Recruiting
Est. primary completion 2027-01-25 · NCT07644286 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Acute Lung Injury, PreventionRecruiting
Est. primary completion 2027-07-31 · NCT05704166 · CT.gov ↗
What to watch
2028 (3)
April 2028 (1)
Phase 4Fibrotic Interstitial Lung DiseaseNot yet recruiting
Est. primary completion 2028-04-30 · NCT07141810 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2Recurrent Acute PancreatitisRecruiting
Est. primary completion 2028-09-01 · NCT06253117 · CT.gov ↗
What to watch
December 2028 (1)
Phase 4Takayasu ArteritisNot yet recruiting
Est. primary completion 2028-12-31 · NCT07325357 · CT.gov ↗
What to watch
2029 (1)
March 2029 (1)
Phase 1Idiopathic Subglottic Stenosis, Subglottic Stenosis (SGS)Not yet recruiting
Est. primary completion 2029-03-31 · NCT07654517 · CT.gov ↗
What to watch
2030 (2)
August 2030 (1)
Phase 2Chronic PancreatitisNot yet recruiting
Est. primary completion 2030-08 · NCT07755813 · CT.gov ↗
What to watch
September 2030 (1)
Phase 2Peritoneal (Metastatic) Cancer, Peritoneal Carcinoma, Peritoneal Carcinosis, Peritoneal Cancer, Peritoneal Carcinomatosis …Not yet recruiting
Est. primary completion 2030-09 · NCT07856914 · CT.gov ↗
What to watch

See the full readout calendar ↗